BIOMAT Database Logo BIOMAT Database Logo

[Treatment of acromegaly with SMS 201-995]. 1988

R Jorde, and S Skare

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000172 Acromegaly A condition caused by prolonged exposure to excessive HUMAN GROWTH HORMONE in adults. It is characterized by bony enlargement of the FACE; lower jaw (PROGNATHISM); hands; FEET; HEAD; and THORAX. The most common etiology is a GROWTH HORMONE-SECRETING PITUITARY ADENOMA. (From Joynt, Clinical Neurology, 1992, Ch36, pp79-80) Inappropriate Growth Hormone Secretion Syndrome (Acromegaly),Somatotropin Hypersecretion Syndrome (Acromegaly),Inappropriate GH Secretion Syndrome (Acromegaly),Hypersecretion Syndrome, Somatotropin (Acromegaly),Hypersecretion Syndromes, Somatotropin (Acromegaly),Somatotropin Hypersecretion Syndromes (Acromegaly),Syndrome, Somatotropin Hypersecretion (Acromegaly),Syndromes, Somatotropin Hypersecretion (Acromegaly)
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015282 Octreotide A potent, long-acting synthetic SOMATOSTATIN octapeptide analog that inhibits secretion of GROWTH HORMONE and is used to treat hormone-secreting tumors; DIABETES MELLITUS; HYPOTENSION, ORTHOSTATIC; HYPERINSULINISM; hypergastrinemia; and small bowel fistula. Octreotide Acetate,Compound 201-995,Octreotide Acetate Salt,SAN 201-995,SM 201-995,SMS 201-995,Sandostatin,Sandostatine,Sandoz 201-995,Compound 201 995,Compound 201995,SAN 201 995,SAN 201995,SM 201 995,SM 201995,SMS 201 995,SMS 201995,Sandoz 201 995,Sandoz 201995

Related Publications

R Jorde, and S Skare
Treatment of acromegaly with long acting somatostatin analogue SMS 201-995.
October 1988, Endocrinologia japonica,
R Jorde, and S Skare
[Long-term treatment of acromegaly and gigantism with octreotide (SMS 201-995)].
February 1992, Nihon Naibunpi Gakkai zasshi,
R Jorde, and S Skare
Treatment of acromegaly with the long-acting somatostatin analog SMS 201-995.
January 1988, The Journal of clinical endocrinology and metabolism,
R Jorde, and S Skare
Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995.
December 1985, The New England journal of medicine,
R Jorde, and S Skare
Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995.
May 1986, The New England journal of medicine,
R Jorde, and S Skare
Therapy of acromegaly with SMS 201-995: long-term studies.
January 1986, Scandinavian journal of gastroenterology. Supplement,
R Jorde, and S Skare
Somatostatin octapeptide (SMS 201-995) in the medical treatment of acromegaly.
January 1986, Scandinavian journal of gastroenterology. Supplement,
R Jorde, and S Skare
Treatment of resistant acromegaly with a long-acting somatostatin analogue (SMS 201-995).
December 1986, Annals of internal medicine,
R Jorde, and S Skare
Successful treatment of ophthalmoplegia in acromegaly with the somatostatin analogue SMS 201-995.
June 1988, The Netherlands journal of medicine,
R Jorde, and S Skare
Growth hormone rebound after cessation of sms 201-995 treatment in acromegaly.
November 1989, The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques,
Copied contents to your clipboard!